Amicus Therapeutics Inc. Chairman and CEO John Crowley was apologetic – and also adamant about trial quality – upon announcing Sept. 13 that the biotech will drop further development of SD101 for epidermolysis bullosa (EB) after a Phase III trial failed to meet its two co-primary endpoints and all of its secondary endpoints.
Crowley offered hope to EB patients, their clinicians and caregivers during a same-day investor call by noting that several other companies also are developing therapies for a disease he called “the most devastating genetic disorder that I have ever witnessed